(Q33202218)

23 July 2017

1 reference

title

Platinum containing regimens for metastatic breast cancer. (English)

1 reference

23 July 2017

1 reference

S Carrick

1

1 reference

23 July 2017

D Ghersi

series ordinal

2

1 reference

23 July 2017

N Wilcken

series ordinal

3

1 reference

23 July 2017

J Simes

series ordinal

4

1 reference

23 July 2017

publication date

1 January 2004

1 reference

Cochrane Database of Systematic Reviews

23 July 2017

published in

1 reference

23 July 2017

issue

2

1 reference

23 July 2017

page(s)

CD003374

1 reference

Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

The platinum agents: a role in breast cancer treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

Prognostic value of serum tetranectin in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB2

10.1002/14651858.CD003374.PUB2

21 January 2018

Identifiers

DOI

1 reference

23 July 2017

1 reference